Literature DB >> 31186262

Incidence of Ductal Carcinoma In Situ in the United States, 2000-2014.

Marc D Ryser1,2, Laura H Hendrix3, Mathias Worni4, Yiling Liu5, Terry Hyslop3, E Shelley Hwang6.   

Abstract

BACKGROUND: In absence of definitive molecular risk markers, clinical management of patients diagnosed with ductal carcinoma in situ (DCIS) remains largely guided by patient and tumor characteristics. In this study, we analyzed recent trends in DCIS incidence and compared them against trends in mammography use.
METHODS: The Surveillance, Epidemiology, and End Results registry was queried for patients diagnosed with DCIS from 2000 to 2014 (18 registries). Joinpoint regression analyses were used to compute age- and race-stratified trends in age-adjusted incidence of DCIS. The patterns of DCIS incidence were compared against mammography utilization data from the National Health Interview Survey.
RESULTS: Between 2000 and 2014, overall DCIS incidence in the U.S. population was stable (P = 0.24). Among age groups 20 to 44 years and 45 to 55 years, DCIS incidence increased by 1.3% (P = 0.001) and 0.6% (P = 0.02) per year, respectively. Although stable among white women, DCIS incidence increased among black women and women of other races by 1.6% (P < 0.001) and 1.0% (P = 0.002) per year, respectively. Mammography uptake correlated well with DCIS incidence, with the exception of women ages 40 to 49 years and black women who experienced an increase in DCIS incidence despite stagnating and decreasing mammography uptake, respectively.
CONCLUSIONS: Overall DCIS incidence rates have remained stable between 2000 and 2014. However, subgroup analyses revealed an increase in incidence among both younger women and black women. IMPACT: DCIS incidence trends did not correlate with the mammography uptake patterns, suggesting that etiologic factors other than screening may be leading to an increased DCIS incidence in these groups. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2019        PMID: 31186262      PMCID: PMC6679771          DOI: 10.1158/1055-9965.EPI-18-1262

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  20 in total

1.  How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach.

Authors:  E J Feuer; L M Wun
Journal:  Am J Epidemiol       Date:  1992-12-15       Impact factor: 4.897

2.  Bias associated with self-report of prior screening mammography.

Authors:  Kathleen A Cronin; Diana L Miglioretti; Martin Krapcho; Binbing Yu; Berta M Geller; Patricia A Carney; Tracy Onega; Eric J Feuer; Nancy Breen; Rachel Ballard-Barbash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06       Impact factor: 4.254

3.  Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ.

Authors:  Mathias Worni; Igor Akushevich; Rachel Greenup; Deba Sarma; Marc D Ryser; Evan R Myers; E Shelley Hwang
Journal:  J Natl Cancer Inst       Date:  2015-09-30       Impact factor: 13.506

Review 4.  Ductal carcinoma in situ: terminology, classification, and natural history.

Authors:  D Craig Allred
Journal:  J Natl Cancer Inst Monogr       Date:  2010

Review 5.  Epidemiology of ductal carcinoma in situ.

Authors:  Karla Kerlikowske
Journal:  J Natl Cancer Inst Monogr       Date:  2010

6.  Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death.

Authors:  Robert E Roses; Banu K Arun; Sara A Lari; Elizabeth A Mittendorf; Anthony Lucci; Kelly K Hunt; Henry M Kuerer
Journal:  Ann Surg Oncol       Date:  2011-04-08       Impact factor: 5.344

7.  Characterizing the impact of 25 years of DCIS treatment.

Authors:  Elissa M Ozanne; Yiwey Shieh; James Barnes; Colleen Bouzan; E Shelley Hwang; Laura J Esserman
Journal:  Breast Cancer Res Treat       Date:  2011-03-09       Impact factor: 4.872

8.  Update on mammography trends: comparisons of rates in 2000, 2005, and 2008.

Authors:  Nancy Breen; Jane F Gentleman; Jeannine S Schiller
Journal:  Cancer       Date:  2010-11-30       Impact factor: 6.860

9.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Authors:  Rowan T Chlebowski; Susan L Hendrix; Robert D Langer; Marcia L Stefanick; Margery Gass; Dorothy Lane; Rebecca J Rodabough; Mary Ann Gilligan; Michele G Cyr; Cynthia A Thomson; Janardan Khandekar; Helen Petrovitch; Anne McTiernan
Journal:  JAMA       Date:  2003-06-25       Impact factor: 56.272

10.  Effect of three decades of screening mammography on breast-cancer incidence.

Authors:  Archie Bleyer; H Gilbert Welch
Journal:  N Engl J Med       Date:  2012-11-22       Impact factor: 91.245

View more
  6 in total

Review 1.  Ductal Carcinoma in Situ: State-of-the-Art Review.

Authors:  Lars J Grimm; Habib Rahbar; Monica Abdelmalak; Allison H Hall; Marc D Ryser
Journal:  Radiology       Date:  2021-12-21       Impact factor: 11.105

2.  Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study.

Authors:  Guannan Wang; Alok Kumar; Wanjun Ding; Preethi Korangath; Tapan Bera; Junxia Wei; Priya Pai; Kathleen Gabrielson; Ira Pastan; Saraswati Sukumar
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-08       Impact factor: 12.779

3.  Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.

Authors:  Jean L Wright; Habib Rahbar; Samilia Obeng-Gyasi; Ruth Carlos; Judy Tjoe; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2021-11-23       Impact factor: 50.717

4.  Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical device.

Authors:  Anna Sarnelli; Matteo Negrini; Emilio Mezzenga; Giacomo Feliciani; Marco D'Arienzo; Antonino Amato; Giovanni Paganelli
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

5.  MiRNA expression deregulation correlates with the Oncotype DX® DCIS score.

Authors:  Olivier Loudig; Megan I Mitchell; Iddo Z Ben-Dov; Christina Liu; Susan Fineberg
Journal:  Breast Cancer Res       Date:  2022-09-12       Impact factor: 8.408

6.  A medicare-based comparative mortality analysis of active surveillance in older women with DCIS.

Authors:  Igor Akushevich; Arseniy P Yashkin; Rachel A Greenup; E Shelley Hwang
Journal:  NPJ Breast Cancer       Date:  2020-10-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.